Aerospace startup Boom says they've proven quiet supersonic flight is possible with their passenger airplanes after a ...

Strength in the pharmaceutical major’s oncology business offset weak China sales, but the company has warned of a potential ...

Fintel reports that on February 13, 2025, UBS upgraded their outlook for AstraZeneca PLC - Depositary Receipt () ...

AstraZeneca is expecting Phase III trial data for seven new medicines in 2025, its CEO said as he confirmed the company’s ...

AstraZeneca’s share price has dropped recently on concerns relating to its Chinese operation, but this may have left the ...

AstraZeneca on Thursday said it could face a fine of up to $4.5 million in China over suspected unpaid import taxes, raising ...

Before taking its repurposed diabetes drug candidate into a phase 2 lupus trial, Conduit Pharmaceuticals is tapping Charles River Laboratories to help test the asset in a preclinical model of the ...

How an agreement set up by the Tories and lauded by Labour fell victim to cost-cutting and UK curbs on drugs expenditure ...

AstraZeneca investors will look past another strong set of quarterly results on Thursday to focus on the main issue ...

AstraZeneca Pharma India plans to sell its 64-acre Bengaluru facility as part of a strategic review by its parent company.

Today, Benzinga's options scanner spotted 9 options trades for AstraZeneca. This isn't normal. The overall sentiment of these ...

Shares of AstraZeneca Pharma India Ltd closed at ₹7,450 on the BSE, down 1.29% ahead of the earnings announcement.